Bladder Cancer Pipeline Outlook, FDA Approvals, Clinical Trials, and Companies 2024 (Updated)

DelveInsight's, "Bladder Cancer Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Bladder Cancer Pipeline Report

* DelveInsight's Bladder Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Bladder Cancer treatment.
* The leading Bladder Cancer Companies working in the market include UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others.
* Promising Bladder Cancer Therapies in the various stages of development include Atezolizumab, PGV001, VAX014, BCG Vaccine, Oncofid-P-B, Oncofid-P-B, and others.
* May 2024:- Eli Lilly and Company- The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.
* May 2024- Merck Sharp & Dohme LLC- The purpose of this study is to assess the safety and efficacy of V940 in combination with pembrolizumab (MK-3475) compared to pembrolizumab alone as an adjuvant treatment for participants with pathologic high-risk muscle-invasive urothelial carcinoma (MIUC) after radical resection. The primary study hypothesis is that V940 in combination with pembrolizumab results in a superior disease-free survival (DFS) as assessed by the investigator compared to pembrolizumab alone in participants with high-risk MIUC after radical resection.
* May 2024:- Ferring Pharmaceuticals- ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States. Multi-center, prospective non-interventional study to collect data on the early use of ADSTILADRIN in the US. Data will be collected from participants, caregivers and prescribing physicians in a real-world setting.

Request a sample and discover the recent advances in Bladder Cancer @ Bladder Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Bladder Cancer Overview

Bladder cancer is a disease that usually begins in the cells that line the inside of the bladder. It typically affects people older than 70 and occurs more often in men. Bladder cancer is the fifth most common form of cancer overall and the fourth most common among men. Bladder cancer usually responds well to treatment when diagnosed early. However, people who have been successfully treated for bladder cancer should be monitored afterward. Bladder cancer can return even years later. About 90 percent of bladder cancers begin in the cells on the surface of the bladder's inner lining.

Bladder cancer Emerging Drugs

* UGN-102: UroGen Pharma Ltd.
* APL 1202 : Asieris Pharmaceuticals
* Trilaciclib: G1 Therapeutics, Inc.
* Catumaxomab: LintonPharm Co.,Ltd.
* VAX 014: Vaxiion Therapeutics

Learn more about Bladder Cancer in clinical trials @ Bladder Cancer Drugs [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Bladder Cancer Therapeutics Assessment

There are approx. 80+ Bladder Cancer companies which are developing the Bladder Cancer therapies. The Bladder Cancer Companies which have their Bladder cancer drug candidates in the most advanced stage, i.e. phase III include, UroGen Pharma Ltd.

DelveInsight's Bladder Cancer pipeline report covers around 100+ products under different phases of clinical development like

* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates

Discover more about Bladder Cancer in development @ Bladder Cancer Clinical Trials [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Bladder Cancer Companies

UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others

The bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical

Bladder Cancer Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

To know more about Bladder Cancer, visit @ Bladder Cancer Segmentation [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Bladder Cancer Pipeline Report

* Coverage- Global
* Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Bladder Cancer Companies- UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others
* Bladder Cancer Therapies- Atezolizumab, PGV001, VAX014, BCG Vaccine, Oncofid-P-B, Oncofid-P-B, and others.

For further information on the Bladder Cancer Pipeline Therapeutics, reach out @ Bladder Cancer Products Development [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Bladder Cancer : Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* UGN-102: UroGen Pharma Ltd.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Trilaciclib: G1 Therapeutics, Inc.
* Early Stage Products (Phase I)
* VAX 014: Vaxiion Therapeutics
* Inactive Products
* Bladder Cancer Key Companies
* Bladder Cancer Key Products
* Bladder Cancer - Unmet Needs
* Bladder Cancer - Market Drivers and Barriers
* Bladder Cancer - Future Perspectives and Conclusion
* Bladder Cancer Analyst Views
* Bladder Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bladder-cancer-pipeline-outlook-fda-approvals-clinical-trials-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.